# OnCo record sipuleucel-t (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sipuleucel-t/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sipuleucel-t" ;
  schema:name "Sipuleucel-T"@en ;
  schema:description "Sipuleucel-T was the first therapeutic cancer vaccine approved (2010): it lengthened survival in metastatic prostate cancer by about four months without shrinking tumours or lowering PSA."@en ;
  schema:url <https://onco.cc/drugs/sipuleucel-t/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sipuleucel-T> ;
  owl:sameAs <http://www.wikidata.org/entity/Q424057> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1001294>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sipuleucel>, <https://doi.org/10.1056/NEJMoa1001294>, <https://www.nice.org.uk/guidance/ta332> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Autologous cellular immunotherapy (antigen-presenting cell vaccine)" ;
  schema:alternateName "Provenge" ;
  onco:approval "US 2010: Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer", "EU 2013: Same (withdrawn 2015 for commercial reasons)" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/shared-antigen-vaccine/> ;
  onco:companies <https://onco.cc/companies/dendreon/> ;
  onco:terms <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/nct06134232/>, <https://onco.cc/trials/impact-sipuleucel-t/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-kantoff-n-engl-j-med/> .